BARCELONA, Spain--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp® (darbepoetin alfa) paired with chemotherapy treatment (every two or every three weeks depending on chemotherapy regimen) appeared to be efficacious with respect to changes in hemoglobin (Hb), with no unexpected adverse events observed when compared to weekly dosing.
